Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-05-15
2007-05-15
Saeed, Kamal A. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
Reexamination Certificate
active
11326277
ABSTRACT:
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
REFERENCES:
patent: 4751292 (1988-06-01), Fox
patent: 5397788 (1995-03-01), Horwell et al.
patent: 5622983 (1997-04-01), Horwell et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0133011 (2004-07-01), Waddell et al.
patent: 2005/0245534 (2005-11-01), Link et al.
patent: 2005/0261302 (2005-11-01), Hoff et al.
patent: 2005/0277647 (2005-12-01), Link et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0079506 (2006-04-01), Linders et al.
patent: 2006/0089349 (2006-04-01), Gundertofte et al.
patent: 2006/0094699 (2006-05-01), Kampen et al.
patent: 2006/0100235 (2006-05-01), Andersen et al.
patent: 2006/0106008 (2006-05-01), Andersen et al.
patent: 2006/0106071 (2006-05-01), Lin et al.
patent: 2006/0111348 (2006-05-01), Kampen et al.
patent: 2006/0111366 (2006-05-01), Andersen et al.
patent: 336356 (1989-04-01), None
patent: 405537 (1990-06-01), None
patent: 740752 (1980-09-01), None
patent: 803348 (1981-09-01), None
patent: 9113081 (1991-09-01), None
patent: 9214697 (1992-09-01), None
patent: 9428885 (1994-12-01), None
patent: 9500146 (1995-01-01), None
patent: 9902145 (1999-01-01), None
patent: 0129007 (2001-04-01), None
patent: 200365983 (2003-08-01), None
patent: 2003075660 (2003-09-01), None
patent: 200411310 (2004-02-01), None
patent: 2004033427 (2004-04-01), None
patent: 2004037251 (2004-05-01), None
patent: 2004056744 (2004-07-01), None
patent: 2004056745 (2004-08-01), None
patent: 2004065351 (2004-08-01), None
patent: 2004089367 (2004-10-01), None
patent: 2004089380 (2004-10-01), None
patent: 2004089416 (2004-10-01), None
patent: 2004089470 (2004-10-01), None
patent: 2004089471 (2004-10-01), None
patent: 2004089896 (2004-10-01), None
patent: 2005016877 (2005-02-01), None
patent: 2005042513 (2005-05-01), None
patent: 2005046685 (2005-05-01), None
patent: 2005047250 (2005-05-01), None
patent: 2005060963 (2005-07-01), None
patent: 2005097764 (2005-10-01), None
patent: 2005103023 (2005-11-01), None
patent: 2005108359 (2005-11-01), None
patent: 2005116002 (2005-12-01), None
patent: 2006002349 (2006-01-01), None
patent: 2006002350 (2006-01-01), None
patent: 2006002361 (2006-01-01), None
patent: 2006012642 (2006-01-01), None
patent: 2006012173 (2006-02-01), None
patent: 2006012226 (2006-02-01), None
patent: 2006012227 (2006-02-01), None
patent: 2006017542 (2006-02-01), None
patent: 2006020598 (2006-02-01), None
patent: 2006024627 (2006-03-01), None
patent: 2006024628 (2006-03-01), None
patent: 2006040329 (2006-04-01), None
patent: 2006048330 (2006-05-01), None
patent: 2006048331 (2006-05-01), None
patent: 2006048750 (2006-05-01), None
patent: 2006049952 (2006-05-01), None
patent: 2006050908 (2006-05-01), None
patent: 2006053024 (2006-05-01), None
patent: 2006066109 (2006-06-01), None
Goodman and Gillman's, The Pharmacological Basis of Therapeutics, Seventh Edition MacMillan Publishing Company New York, NY (1985).
Seckl J.R et al, EndocrinologyMinireview: 11β-Hydroxysteroid Dehydrogenase Type 1—A Tissue-Specific Amplifier of Glucocorticoid Action142: 1371-1376 (2001).
Higuchi, T and Stella V. Pro-drugs as Novel Delivery Systems vol. 14.
Roche E, Bioreversible Carriers in Drug Design APA and Pergamon Press (1987).
Jones C.D et al Journal Org. Chem.Effects of Substituent Modification on Face Selection in Reduction63: 2758-2760 (1998).
Greene T.W, P.G.M Wuts “Protective Groups in Organic Synthesis” 3rded. (1999).
Han et al, J. Am. Chem. Soc.Properly Designed Modular Asymmetric Synthesis for Enantiopure Sulfinamise Auxiliaries from N-Sulfonyl 1,2,3-oxathiazolidine-2-oxide Agents124 :7880-7881 (2002).
Walker B.R et al. Journal of Clin. Endocrinology and Met.Carbenoxolone increases Hepatic insulin Sensitivity in Man: A Novel Role for 11-Oxosteroid Reductase in Enhancing Glucocorticoid Receptor Activation80 3155-3159 (1995).
Billaudel et al, Horm. Metab. Res.Direct Effect of Corticosterone upon I nsulin Secretion Studied by Three Different Techniques11: 555-560 (1979).
Davani et al, Journal of Biol. Chem.Type 1 11β-Hydroxysteroid Dehydrogenase Mediates Glucocorticoid Activation and Insulin Release in Pancreatic Islets275: 34841-34844 (2000).
Paterson J.M et al Proc. Natl. Acad. Sci. USAMetabolic Syndrome without Obesity: Hepatic Overexpression of 11{beta}-hydroxysteroid dehydrogenase type 1 in Transgenic Mice101: 7088-7093 (2004).
Montague et al, Diabetes,Causes and Consequences of Visceral Adiposity49: 883-888 (2000).
Orstater et al, Diabetes Metab.Res. Rev. Regulation of 11β-hydroxysteroid dehydrogenase Type 1 and Glucose-stimulated Insulin Secretion in Pancreatic Islets of Langerhans21: 359-366 (2005).
Masuzaki et al, ScienceA Transgenic Model of Visceral Obesity and the Metabolic Syndrome294: 2166-2170 (2001).
Walker, B.R., Clinical ScienceCorticosteroids and Vascular Tone: Mapping the Messenger Maze82: 597-605 (1992).
Pirpiris M., HypertensionPressor Responsiveness in Corticosteroid-Induced Hypertension in Humans19: 567-574 (1992).
Masuzaki et al, Journal of Clin Invest.Transgenic Amplification of Glucocorticoid Action in Adipose Tissue Causes High Blood Pressure in Mice112(1): 83-90 (2003).
Rook, G.A.W., Baillleres Clinical Endocrinology. and MetabolismGlucocorticoids and Immune Function13(4): 567-581 (1999).
Belanoff, J.K., Journal of Psychiatric ResearchCorticosteroids and Cognition35: 127-145 (2001).
Baxter. J.D., Pharm. TherGlucoccorticoid Hormone Action2: 605-659 (1976).
Bertagna, X, Pituitary TumorsCushing's DiseaseChapter 13 Section 3: 592-612 (2002).
Walker, et al, PNASPreventing local regeneration of glucocorticoids by 11—-hydroxysteroid dehydrogenase type 1enhances angiogenesis102: 12165-12170 (2005).
Hodge, G., Experimental PhysiologySalr-Sensitive Hypertension Resulting from Nitric Oxide Synthase Inhibition is associated with Loss of Regulation of Angiotensin II87(1): 1-8 (2002).
Good man and Gilman's, The Pharmacological Basis of Therapeutics, seventh Edition MacMillian Publishing Company New York, NY (1985), reference not included.
Issa, A.M., The Journal of NeuroscienceHypothalamic-Pituitary-Adrenal Activivty in Aged, Cognitively Impaired and Cognitively Unimpaired Rats10(10): 3247-3254 (1990).
Boscaro, M., The LancetCushing's Syndrome357: 783-791 (2001).
Orth, D., The New England Journal of MedicineNormal Hypothalamic-Pituitary-Adrenal Physiology332 (12): 791-803 (1995).
Cooper., M.S., BoneExpression and Functional Consequences of 11β-Hydroxysteroid Dehydrogenase Activity in Human Bone27(3): 375-381 (2000).
Cooper et al., BoneOsteoprogenitor Cells in Cell Populations Derived From Mouse and Rat Calvaria Differ in Their Response to Corticosterone, Cortisol and Cortisone23(2): 119-125 (1998).
Bland, R., Journal of EndocrinologyCharacterization of 11β-Hydroxysteroid Dehydrogenase Activityand Corticosteroid Receptor Expression in Human Osteosarcoma Cell Lines161: 455-464 (1999).
Rauz, S., Q. J. MedInhibition if 11β-Hydroxysteroid Dehydrogenase type 1 lower Intraocular Pressure in Patients with Ocular Hypertension96: 481-490 (2003).
Tronche, F Nature GeneticsDisruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety23: 99-103 (1999).
Lupien, S., NatureCortisol Levels during Human aging Predict Hippocampal Atrophy and memory deficits1(1): 69-103 (1998).
Stokes, John Invest. Ophthalmology and Vis. Sci.Altered Peripheral Sensitivity to Glucocorticoids in Primary Open-Angle Glaucoma44(12): 5163-5167 (2003).
Rauz, S., Invest Ophthalmology & Vis. ScienceExpression and Putative Role of 11β-Hydroxyster
Dinges Jurgen
Kurukulasuriya Ravi
Link James T.
Patel Jyoti R.
Rohde Jeffrey J.
Abbott Laboratories
Parial Andrew M.
Young Shawquia
LandOfFree
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788824